A recent healthcare analysis shows that a novel, catheter-based endovascular system for creating haemodialysis access offers quality-of-life benefits and cost savings compared to the traditional surgical approach in end-stage renal disease patients. The retrospective analysis comparing the everlinQ endoAVF System from TVA Medical with surgical arteriovenous fistula creation was presented at ISPOR 2018 (19–23 May, Baltimore, USA), a leading global conference for health economics and outcomes research.
“Over 7% of the Medicare budget is spent on managing patients with end-stage renal disease. Non-functional arteriovenous fistulae lead to prolonged central venous catheter use, increasing the risk of infection and hospitalisation and contributing to the rising costs of treating haemodialysis patients. Procedures that facilitate a functional fistula, improve patient outcomes and save costs are an important advancement for patients and payers,” says Adam L Berman, CEO of TVA Medical. “We are encouraged by the results of this analysis and the benefit for patients.”
The retrospective analysis compared endoAVF patients from the Novel Endovascular Access Trial (NEAT, NCT02036671) with propensity-score matched surgical arteriovenous fistula patients from the US Renal Data System for one year after fistula creation.
